Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TSLA
3. NOW
4. TXN
5. AMD
6. GOOG
7. INTC
8. CSX
9. KNX
10. IBM

Go back to Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma
(NASDAQ: DRTS) Delayed: 13.24 +0.23 (1.77%)
Previous Close $13.01    52 Week High $ 
Open $13.04    52 Week Low $ 
Day High $13.51    P/E N/A 
Day Low $12.80    EPS $ 
Volume 456,518       

(NASDAQ: DRTSW) Delayed: 3.54 +0.24 (7.27%)
Previous Close $3.30    52 Week High $ 
Open $3.45    52 Week Low $ 
Day High $3.71    P/E N/A 
Day Low $3.45    EPS $ 
Volume 4,143